FDA supplemental approval: Oxycodone AND Acetaminophen (REMS)

AI Summary

This is an FDA supplemental approval action granting a REMS (Risk Evaluation and Mitigation Strategy) for oxycodone and acetaminophen tablet formulations (325 mg acetaminophen + 7.5 mg or 10 mg oxycodone hydrochloride). The record confirms regulatory authorization but does not report clinical trial outcomes, efficacy data, or comparative benefit evidence.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for an oxycodone–acetaminophen combination product; this is a regulatory action, not a clinical efficacy study.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory action does not convey clinical efficacy, safety trial results, or comparative effectiveness. Clinicians should consult the approved labeling, prescribing information, and the REMS requirements (not detailed in this record) for guidance on appropriate use and risk mitigation.

Caveats

• This record does not contain clinical trial results, efficacy endpoints, or safety data.
• No information on REMS requirements, implementation details, or contraindications is provided in this regulatory notification.
• Approval of a REMS indicates risk management concern but does not establish comparative clinical benefit.
• No patient population, dosing guidance, or indication is specified in this regulatory summary.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.